The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer
Human epidermal growth factor receptor 2 (HER-2) overexpressed breast cancer has traditionally been considered as an aggressive disease with high risk of systemic and brain metastases and poor prognosis. Nowadays, we have many HER-2 targeting treatments that have radically changed patients’ outcomes...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.09.044 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126510611628032 |
|---|---|
| author | Larissa Russo-Vorms Christoforos Astaras José Sandoval Maxime Borgeaud Alexandre Bodmer |
| author_facet | Larissa Russo-Vorms Christoforos Astaras José Sandoval Maxime Borgeaud Alexandre Bodmer |
| author_sort | Larissa Russo-Vorms |
| collection | DOAJ |
| description | Human epidermal growth factor receptor 2 (HER-2) overexpressed breast cancer has traditionally been considered as an aggressive disease with high risk of systemic and brain metastases and poor prognosis. Nowadays, we have many HER-2 targeting treatments that have radically changed patients’ outcomes. Among the oldest ones, trastuzumab, pertuzumab, lapatinib and trastuzumab-emtansine have been for some years the backbone of established therapies. New drugs, such as tucatinib, trastuzumab-deruxtecan, pyrotinib, neratinib and margetuximab, have recently joined the therapeutic arsenal, revolutionizing the therapeutic field of this disease. Many other drugs are currently under development and give hope, with encouraging results to heavily pretreated patients or those with central nervous system metastasis. |
| format | Article |
| id | doaj-art-82f9b3de20fc40708b6592b3611ad7e8 |
| institution | Kabale University |
| issn | 2673-2106 |
| language | English |
| publishDate | 2021-10-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-82f9b3de20fc40708b6592b3611ad7e82024-12-12T17:11:11ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062021-10-0193The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast CancerLarissa Russo-VormsChristoforos AstarasJosé SandovalMaxime BorgeaudAlexandre BodmerHuman epidermal growth factor receptor 2 (HER-2) overexpressed breast cancer has traditionally been considered as an aggressive disease with high risk of systemic and brain metastases and poor prognosis. Nowadays, we have many HER-2 targeting treatments that have radically changed patients’ outcomes. Among the oldest ones, trastuzumab, pertuzumab, lapatinib and trastuzumab-emtansine have been for some years the backbone of established therapies. New drugs, such as tucatinib, trastuzumab-deruxtecan, pyrotinib, neratinib and margetuximab, have recently joined the therapeutic arsenal, revolutionizing the therapeutic field of this disease. Many other drugs are currently under development and give hope, with encouraging results to heavily pretreated patients or those with central nervous system metastasis.https://doi.org/10.36000/hbT.OH.2021.09.044 |
| spellingShingle | Larissa Russo-Vorms Christoforos Astaras José Sandoval Maxime Borgeaud Alexandre Bodmer The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer healthbook TIMES. Oncology Hematology |
| title | The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer |
| title_full | The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer |
| title_fullStr | The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer |
| title_full_unstemmed | The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer |
| title_short | The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer |
| title_sort | rapidly changing treatment landscape of systemic therapy for her 2 positive metastatic breast cancer |
| url | https://doi.org/10.36000/hbT.OH.2021.09.044 |
| work_keys_str_mv | AT larissarussovorms therapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT christoforosastaras therapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT josesandoval therapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT maximeborgeaud therapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT alexandrebodmer therapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT larissarussovorms rapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT christoforosastaras rapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT josesandoval rapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT maximeborgeaud rapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer AT alexandrebodmer rapidlychangingtreatmentlandscapeofsystemictherapyforher2positivemetastaticbreastcancer |